Evofosfamide combined with gemcitabine/nab-paclitaxel in patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma (PAC): Results of a phase I trial.

Authors

Mitesh J. Borad

Mayo Clinic, Scottsdale, AZ

Mitesh J. Borad , Eunice Lee Kwak , Andrea Wang-Gillam , Ayman Ibrahim , Julie Aldridge , Anthony J. Olszanski

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

A single-arm, open-label, phase I study of CPI-613 (Devimistat) in combination with gemcitabine and nab-paclitaxel for patients with locally advanced or metastatic pancreatic adenocarcinoma.

First Author: Angela Tatiana Alistar

insert_chart_outlined

Poster

2024 ASCO Gastrointestinal Cancers Symposium

bookmark_border

Preliminary results of a phase II study of surufatinib plus sintilimab, nab-paclitaxel and gemcitabine (AG) as first-line therapy in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (mPDAC).

First Author: Dong-Sheng Zhang

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: BIBABRAX study.

First Author: Jaime Feliu Batlle

insert_chart_outlined

Poster

2019 Gastrointestinal Cancers Symposium

bookmark_border

GA CPI 613: A single arm, open-label phase I study of CPI-613 in combination with gemcitabine and nab-paclitaxel for patients with locally advanced or metastatic pancreatic cancer.

First Author: Angela Tatiana Alistar